Fibroblast growth factor receptor risk signature predicts patient prognosis and immunotherapy resistance in colorectal cancer
Together, these data support FRS positively correlates with poor prognosis and therapy resistance. The PHA-793887 could be a potential FRS inhibitor to improving the effectiveness of CRC management via bolstering antitumor immunity.
Authors
- Tiankuo Luan
- Liuying Li (ORCID: https://orcid.org/0000-0001-7826-1276)
- Daqiang Song
- Qian Xiao (ORCID: https://orcid.org/0000-0001-8855-6561)
- Zhiling Pan
- Qianxue Wu
- Xiaofang Li (ORCID: https://orcid.org/0000-0002-0604-849X)
- Xiang Zhang (ORCID: https://orcid.org/0000-0002-7543-8352)
- Guoqing Yao (ORCID: https://orcid.org/0009-0009-5075-2837)
Institutions
- Affiliated Hospital of Southwest Medical University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- Baise University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.3389/fimmu.2024.1493673
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.84